TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I Study of GW642444M- A Randomized, Double Blind, Placebo Controlled, Parallel-group, 7 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Dose of GW642444M From a Novel Dry Powder Device in Healthy Japanese Male Subjects -
Brief Summary: This is a randomized, double blind, placebo controlled, parallel-group, 7 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose of GW642444M from a novel dry powder device in healthy Japanese male subjects.


Options:
A: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm 1
B: Arm Label: GW642444M 25mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M, Drug: placebo | Arm Label: GW642444M 50mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M | Arm Label: GW642444M 100mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M, Drug: placebo | Arm Label: GW642444H 100mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444H, Drug: placebo | Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: GW642444M; Assigned to Arm(s): GW642444M 100mcg, GW642444M 25mcg, GW642444M 50mcg | Intervention Type: DRUG; Name: GW642444H; Assigned to Arm(s): GW642444H 100mcg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): GW642444H 100mcg, GW642444M 100mcg, GW642444M 25mcg, placebo
C: Arm Label: FF/VI 200/25mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: GW685698/GW642444 | Arm Label: Fluticasone propionate 500mcg twice daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: CCI18781 | Intervention Type: DRUG; Name: GW685698/GW642444; Assigned to Arm(s): FF/VI 200/25mcg once daily | Intervention Type: DRUG; Name: CCI18781; Assigned to Arm(s): Fluticasone propionate 500mcg twice daily
D: Arm Label: LABA; Type: EXPERIMENTAL; Interventions: Drug: GW642444 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GW642444; Assigned to Arm(s): LABA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of CVD Education and Problem-Solving Training in Urban Diabetics
Brief Summary: The purpose of this study is to determine if patient education and problem-solving training, delivered in self-study, group, and individual intervention modalities, will produce substantial improvements in CVD risk profile via improved self management in urban African Americans with type 2 diabetes and a high CVD risk profile.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: evidence based decision aid, Behavioral: Possible reimbursement 4th IVF/ICSI cycle when necessary | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: evidence based decision aid; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Possible reimbursement 4th IVF/ICSI cycle when necessary; Assigned to Arm(s): 1
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Self Study; Type: EXPERIMENTAL; Interventions: Behavioral: Education + Problem-Solving Training Self-Study | Arm Label: Group Problem-Solving Training; Type: EXPERIMENTAL; Interventions: Behavioral: Education + Group Problem-Solving Training | Arm Label: Individual Problem-Solving Training; Type: EXPERIMENTAL; Interventions: Behavioral: Education + Individual Problem-Solving Training | Intervention Type: BEHAVIORAL; Name: Education + Problem-Solving Training Self-Study; Assigned to Arm(s): Self Study | Intervention Type: BEHAVIORAL; Name: Education + Group Problem-Solving Training; Assigned to Arm(s): Group Problem-Solving Training | Intervention Type: BEHAVIORAL; Name: Education + Individual Problem-Solving Training; Assigned to Arm(s): Individual Problem-Solving Training | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Heart disease; Type: N/A; Interventions: N/A | Arm Label: Healthy adults; Type: N/A; Interventions: N/A
D: Arm Label: communication skills training; Type: EXPERIMENTAL; Interventions: Behavioral: patient training in shared decision making | Arm Label: cognitive training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: cognitive training | Intervention Type: BEHAVIORAL; Name: patient training in shared decision making; Assigned to Arm(s): communication skills training | Intervention Type: BEHAVIORAL; Name: cognitive training; Assigned to Arm(s): cognitive training

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Antidepressants in Chronic Back Pain
Brief Summary: This 12 week placebo controlled clinical trial tests the individual and combined effects of an antidepressant medication and cognitive behavioral therapy for chronic back pain.


Options:
A: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran
B: Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Milnacipran | Arm Label: Milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran, Sugar pill
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran 100mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Milnacipran 100mg; Assigned to Arm(s): Milnacipran
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: desipramine hydrochloride | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: cognitive behavioral therapy | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: desipramine hydrochloride, Behavioral: cognitive behavioral therapy | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: benztropine mesylate 0.125 mg daily | Intervention Type: BEHAVIORAL; Name: cognitive behavioral therapy; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: desipramine hydrochloride; Assigned to Arm(s): Arm 3 | Intervention Type: BEHAVIORAL; Name: cognitive behavioral therapy; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: benztropine mesylate 0.125 mg daily; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: desipramine hydrochloride; Assigned to Arm(s): Arm 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Antidepressants in Chronic Back Pain
Brief Summary: This 12 week placebo controlled clinical trial tests the individual and combined effects of an antidepressant medication and cognitive behavioral therapy for chronic back pain.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: desipramine hydrochloride | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: cognitive behavioral therapy | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: desipramine hydrochloride, Behavioral: cognitive behavioral therapy | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: benztropine mesylate 0.125 mg daily | Intervention Type: BEHAVIORAL; Name: cognitive behavioral therapy; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: desipramine hydrochloride; Assigned to Arm(s): Arm 3 | Intervention Type: BEHAVIORAL; Name: cognitive behavioral therapy; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: benztropine mesylate 0.125 mg daily; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: desipramine hydrochloride; Assigned to Arm(s): Arm 1
B: Arm Label: Pain Ed; Type: EXPERIMENTAL; Interventions: Behavioral: Pain Ed, Other: Usual Care | Arm Label: CBT for Pain; Type: EXPERIMENTAL; Interventions: Behavioral: CBT for Pain, Other: Usual Care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Pain Ed; Assigned to Arm(s): Pain Ed | Intervention Type: BEHAVIORAL; Name: CBT for Pain; Assigned to Arm(s): CBT for Pain | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): CBT for Pain, Pain Ed, Usual Care
C: Arm Label: CBT-I; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I) | Arm Label: CBT-P; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for Pain (CBT-P) | Arm Label: Waitlist Control (WLC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for Insomnia (CBT-I); Assigned to Arm(s): CBT-I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for Pain (CBT-P); Assigned to Arm(s): CBT-P
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducative program in fibromyalgic patients | Intervention Type: BEHAVIORAL; Name: Psychoeducative program in fibromyalgic patients; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates
Brief Summary: The low molecular weight heparin nadroparin is used for anticoagulation of the extracorporeal hemofiltration circuit. Continuous hemofiltration is a renal replacement modality for intensive care patients with acute renal failure. Up to now it is not known whether nadroparin is removed by hemofiltration or not. Accumulation would increase the risk of bleeding.

Aim of the present study is to determine

1. whether nadroparin accumulates in plasma
2. whether nadroparin is removed by filtration and whether removal depends on hemofiltration dose
3. the effects of nadroparin during critical illness on coagulation and anticoagulation


Options:
A: Arm Label: Continuous Venovenous Hemofiltration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Continuous Venovenous Hemofiltration (CVVH) | Arm Label: Continuous Venovenouos Hemodialysis; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Continuous Venovenous Hemodialysis (CVVHD) | Intervention Type: PROCEDURE; Name: Continuous Venovenous Hemofiltration (CVVH); Assigned to Arm(s): Continuous Venovenous Hemofiltration | Intervention Type: PROCEDURE; Name: Continuous Venovenous Hemodialysis (CVVHD); Assigned to Arm(s): Continuous Venovenouos Hemodialysis
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous venvenous hemofiltration (CVVH) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous venovenous hemodialysis (CVVHD) | Intervention Type: DEVICE; Name: Continuous venvenous hemofiltration (CVVH); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Continuous venovenous hemodialysis (CVVHD); Assigned to Arm(s): 2
C: Arm Label: Standard Anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Citrasate; Type: EXPERIMENTAL; Interventions: Drug: Citrasate | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Standard Anticoagulation | Intervention Type: DRUG; Name: Citrasate; Assigned to Arm(s): Citrasate
D: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates
Brief Summary: The low molecular weight heparin nadroparin is used for anticoagulation of the extracorporeal hemofiltration circuit. Continuous hemofiltration is a renal replacement modality for intensive care patients with acute renal failure. Up to now it is not known whether nadroparin is removed by hemofiltration or not. Accumulation would increase the risk of bleeding.

Aim of the present study is to determine

1. whether nadroparin accumulates in plasma
2. whether nadroparin is removed by filtration and whether removal depends on hemofiltration dose
3. the effects of nadroparin during critical illness on coagulation and anticoagulation


Options:
A: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h
B: Arm Label: Early renal replacement therapy; Type: EXPERIMENTAL; Interventions: Device: Dialysis with continuous renal replacement therapy, Device: Mechanical ventilator, Drug: Anti-Bacterial Agents, Drug: Vasopressors | Arm Label: Conventional renal replacement therapy; Type: PLACEBO_COMPARATOR; Interventions: Device: Dialysis with continuous renal replacement therapy, Device: Mechanical ventilator, Drug: Anti-Bacterial Agents, Drug: Vasopressors | Intervention Type: DEVICE; Name: Dialysis with continuous renal replacement therapy; Assigned to Arm(s): Conventional renal replacement therapy, Early renal replacement therapy | Intervention Type: DEVICE; Name: Mechanical ventilator; Assigned to Arm(s): Conventional renal replacement therapy, Early renal replacement therapy | Intervention Type: DRUG; Name: Anti-Bacterial Agents; Assigned to Arm(s): Conventional renal replacement therapy, Early renal replacement therapy | Intervention Type: DRUG; Name: Vasopressors; Assigned to Arm(s): Conventional renal replacement therapy, Early renal replacement therapy
C: Arm Label: SLED; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Arm Label: CVVHD; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Intervention Type: PROCEDURE; Name: Renal replacement therapy; Assigned to Arm(s): CVVHD, SLED
D: Arm Label: high volume hemofiltration; Type: EXPERIMENTAL; Interventions: Procedure: high volume hemofiltration | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard care | Intervention Type: PROCEDURE; Name: high volume hemofiltration; Assigned to Arm(s): high volume hemofiltration | Intervention Type: PROCEDURE; Name: standard care; Assigned to Arm(s): standard care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates
Brief Summary: The low molecular weight heparin nadroparin is used for anticoagulation of the extracorporeal hemofiltration circuit. Continuous hemofiltration is a renal replacement modality for intensive care patients with acute renal failure. Up to now it is not known whether nadroparin is removed by hemofiltration or not. Accumulation would increase the risk of bleeding.

Aim of the present study is to determine

1. whether nadroparin accumulates in plasma
2. whether nadroparin is removed by filtration and whether removal depends on hemofiltration dose
3. the effects of nadroparin during critical illness on coagulation and anticoagulation


Options:
A: Arm Label: AKI requring CRRT and use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with regional citrate anticoagulation | Arm Label: AKI requring CRRT and not use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with no anticoagulation or heparin | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with regional citrate anticoagulation; Assigned to Arm(s): AKI requring CRRT and use regional citrate anticoagulation | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with no anticoagulation or heparin; Assigned to Arm(s): AKI requring CRRT and not use regional citrate anticoagulation
B: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h
C: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy
D: Arm Label: heparin; Type: PLACEBO_COMPARATOR; Interventions: Device: citrate regional anticoagulation | Arm Label: citrate regional anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: citrate regional anticoagulation | Intervention Type: DEVICE; Name: citrate regional anticoagulation; Assigned to Arm(s): heparin | Intervention Type: DEVICE; Name: citrate regional anticoagulation; Assigned to Arm(s): citrate regional anticoagulation, heparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates
Brief Summary: The low molecular weight heparin nadroparin is used for anticoagulation of the extracorporeal hemofiltration circuit. Continuous hemofiltration is a renal replacement modality for intensive care patients with acute renal failure. Up to now it is not known whether nadroparin is removed by hemofiltration or not. Accumulation would increase the risk of bleeding.

Aim of the present study is to determine

1. whether nadroparin accumulates in plasma
2. whether nadroparin is removed by filtration and whether removal depends on hemofiltration dose
3. the effects of nadroparin during critical illness on coagulation and anticoagulation


Options:
A: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h
B: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy
C: Arm Label: 1 prostacyclin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: prostacyclin | Arm Label: 2 heparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: heparin | Intervention Type: DRUG; Name: prostacyclin; Assigned to Arm(s): 1 prostacyclin group | Intervention Type: DRUG; Name: heparin; Assigned to Arm(s): 2 heparin group
D: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates
Brief Summary: The low molecular weight heparin nadroparin is used for anticoagulation of the extracorporeal hemofiltration circuit. Continuous hemofiltration is a renal replacement modality for intensive care patients with acute renal failure. Up to now it is not known whether nadroparin is removed by hemofiltration or not. Accumulation would increase the risk of bleeding.

Aim of the present study is to determine

1. whether nadroparin accumulates in plasma
2. whether nadroparin is removed by filtration and whether removal depends on hemofiltration dose
3. the effects of nadroparin during critical illness on coagulation and anticoagulation


Options:
A: Arm Label: Early RRT strategy; Type: EXPERIMENTAL; Interventions: Procedure: Early RRT strategy | Arm Label: Delayed RRT strategy; Type: EXPERIMENTAL; Interventions: Procedure: Delayed RRT strategy | Intervention Type: PROCEDURE; Name: Early RRT strategy; Assigned to Arm(s): Early RRT strategy | Intervention Type: PROCEDURE; Name: Delayed RRT strategy; Assigned to Arm(s): Delayed RRT strategy
B: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h
C: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
D: Arm Label: Early initiation of RRT; Type: EXPERIMENTAL; Interventions: Procedure: Renal Remplacement Therapy | Arm Label: Deferred RRT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal Remplacement Therapy | Intervention Type: PROCEDURE; Name: Renal Remplacement Therapy; Assigned to Arm(s): Deferred RRT, Early initiation of RRT

Answer: B